齐拉西酮的血药浓度与其治疗精神分裂症疗效的相关性分析

目的 探讨齐拉西酮在中国精神分裂症患者体内的血药浓度与临床疗效的关系.方法 采用超高效液相色谱-质谱联用（UPLC-MS/MS）的方法测定41例精神分裂症患者体内齐拉西酮的血浆药物浓度,疗效评定采用阳性与阴性症状量表（PANSS）评分,用SPSS 13.0统计软件包对血药浓度与疗效评分进行统计分析.结果 治疗1、2、3、4周末的齐拉西酮血药峰浓度与1、2、3、4周末的PANSS减分率无相关性,而3、4周末的平均稳态谷浓度与4周末的PANSS减分率呈正相关（P〈0.05）.同时,将稳态血-药谷浓度分为小于110.0 ng·ml-1组和大于110.0 ng·mL-1组患者的疗效进行比较,结果前者的PANSS减分率明显低于后者,两者差异有统计学意义（P〈0.05）.结论 根据本实验研究结果,初步得出齐拉西酮的临床疗效与其稳态谷浓度高低有关,其稳态谷浓度〉110.0 ng·mL-1时,疗效较好.

Correlation between plasma concentration and clinical efficacy of ziprasidone

Objective To determine the relationship between plasma concentration and clinical efficacy of ziprasidone in Chinese schizophrenics.Methods Ziprasidone plasma sample concentrations were determined by UPLC-MS/MS.Efficacy was measured by the positive and negative syndrome scale（PANSS）scores,and the relationship between plasma concentration and clinical efficacy of ziprasidone was analyzed by SPSS 13.0.Results The peak concentrations of aripiprazole on weekend 1,2,3,and 4 did not correlate with the decreased ratios of PANSS scores,which were positively correlated with the average steady state trough concentrations of ziprasidone on weekend 3 and 4（P〈0.05）.The PANSS scores at above 110.0 ng·mL-1 decreased significantly compared with the lower concentration（P〈0.05）.Conclusion The steady state trough concentrations of ziprasidone are correlative with the efficacy scores,with better results above 110.0 ng·mL-1.